Persistent Underutilization of Systemic Therapy for Atopic Dermatitis Highlights Gap Between Need and Care
RAD 2025: Mobile health data reveal a troubling decline in systemic treatment for moderate to severe atopic dermatitis, underscoring issues in access and clinical inertia.
Dupilumab Monotherapy Improves AD Severity and Pigmentation in People With Skin of Color
Dupilumab monotherapy showed significant improvements in atopic dermatitis symptoms in patients with skin of color, according to late-breaking data presented at RAD 2025.
Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years
RAD 2025: Adults and adolescents treated with nemolizumab experienced rapid onset of action and robust improvements in pruritis, sleep, and quality of life up to 2 years.
Mona Shahriari, MD: Explore the Psychosocial Burden of Atopic Dermatitis with Your Patients—Ask Questions
RAD 2025: Mona Shahriari, MD, underscored the cumulative life impact of atopic dermatitis, reminding clinicians that there is always far more to the condition than meets the clinical eye.
Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis
RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.
Nemolizumab Improves Pruritis, Sleep Within 2 Days When Added to Standard Topical Therapy for Atopic Dermatitis
RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.
Dupilumab Sustains Long-Term Reduction of Staphylococcus aureus in Patients with Atopic Dermatitis
RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.
INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis
RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.
Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study
RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.
Roflumilast Cream 0.15% Demonstrates Safety, Tolerability in Individuals With Atopic Dermatitis With Prior Treatment Failures
RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.
Real-World Abrocitinib Study Shows Most Patients Maintain Consistent Dosing in Atopic Dermatitis Treatment
RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.
Patient Survey Highlights Importance of Itch Relief, Personalized Guidance in Atopic Dermatitis Treatment
RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.
Long-Term Roflumilast Data Show Durable Efficacy in Young Children and Adults with Atopic Dermatitis
RAD 2025: Arcutis Biotherapeutics will present promising long-term data on roflumilast cream, focused on effectiveness and safety for treating atopic dermatitis in young children.
Women’s Health Takeaways for Primary Care: Expert Insights From ACOG 2025
Hear experts' takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.
From HPV to GLP-1 RA: Primary Care Quiz on Recent Women’s Health & Endocrine Evidence
From HPV vaccination to PCOS management, this quiz is designed for primary care providers who want to stay ahead in women's health.
Older Adults are Open to Cognitive Assessment for Dementia in Primary Care But Obstacles Loom Large, a New Study Finds
A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.
The Weekly Dose: Advancements in Colonoscopy, AI for Mammography, and Telemedicine Antibiotic Stewardship
Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.
Social Determinants of Health Affect Use of HRT During Menopause, Study Suggests
Social determinants including partner status, smoking history, and BMI were significantly associated with reduced access to effective hormone therapy for menopausal women.
Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation
Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.
Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD
ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.
ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia
A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.
OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer
ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.
Phase 2 Dose-Finding Study of Intranasal Epinephrine Powder (NS002) Supports Development for Regulatory Submission
Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.
Novel Resorbable Sinonasal Implant Significantly Reduces Symptoms in Treatment-Resistant CRS
Lyra Pharmaceuticals designed the implant, which provides 6 months of continuous delivery of the anti-inflammatory mometasone furoate.
New Data on Atopic Dermatitis for Frontline Clinicians
Preview of 10 new studies on managing atopic dermatitis, including biologics, treatment barriers, and innovative care strategies for clinicians.
Regeneron Phase 2b Study Shows Antibodies Help Preserve Lean Mass During Weight Loss with Semaglutide
Interim results from COURAGE trial suggest combining semaglutide with muscle-preserving antibodies significantly enhances fat loss while preserving lean mass in obesity treatment.
High-Quality Macronutrients Key to Cardiovascular Risk Reduction, Large Cohort Study Finds
Research reveals that the quality of foods in low-carb and low-fat diets significantly impacts heart health, emphasizing whole, plant-based options.
Moderna COVID-19 Vaccine mNEXSPIKE FDA-Approved Under New Eligibility Guidelines
Moderna's mRNA-1283 vaccine gains FDA approval for high-risk groups, following a significant shift in COVID-19 vaccination guidelines by federal health agencies.
Kennedy's First Pass at US Vaccine Policy: ACIP Guidance Reversed, Clinical Trials Amended, WHO Abandoned
Kennedy over 2 weeks has introduced changes in vaccination recommendations and research policy that undermine already tenuous public trust and understanding.
Blood-Based Testing for Colorectal Cancer Screening is Not Quite Ready for Prime Time, Expert Says
Mark Fendrick, MD, thinks that right now, the relative accuracy of blood-based tests for CRC compared with available alternatives is not quite comparable. He explains.
